Somatostatin-like immunoreactivity in the cerebrospinal fluid of aged patients with Parkinson's disease. The effect of dopatherapy.

Abstract

Cerebrospinal fluid (CSF) somatostatin concentrations were measured in 35 aged patients with Parkinson's disease (mean age, 79.5 years) and 11 control subjects (mean age, 82.3 years). In patients with Parkinson's disease the levels of somatostatin-like immunoreactivity were lower than in controls (P less than .02); these values were lowest in the untreated group. Somatostatin-like immunoreactivity levels in the CSF tended to increase with treatment but not significantly (P = .11). Somatostatin values were not correlated to age, sex, or duration of the disease. Somatostatin concentrations tended to be lower in more severely affected patients with higher scores on the Hoehn and Yahr (P = .13) and Webster staging scales (P = .13) and lower scores on Mini-Mental State (P = .10), but without statistical significance for these correlations.

• Authors: H Masson, I Popescu, D Strubel, H Cramer, F Kuntzmann
• Journal: Journal of the American Geriatrics Society (J Am Geriatr Soc) Vol. 38 Issue 1 Pg. 19-24 (Jan 1990) ISSN: 0002-8614 [Print] United States
• PMID: 1688571 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Bromocriptine
• Levodopa
• Somatostatin
• Hydroxyindoleacetic Acid
• Benserazide
• Homovanillic Acid

Topics

• Aged
• Aged, 80 and over
• Benserazide (therapeutic use)
• Bromocriptine (therapeutic use)
• Cognition Disorders (cerebrospinal fluid, drug therapy)
• Female
• Homovanillic Acid (cerebrospinal fluid)
• Humans
• Hydroxyindoleacetic Acid (cerebrospinal fluid)
• Levodopa (therapeutic use)
• Male
• Parkinson Disease (cerebrospinal fluid, drug therapy)
• Severity of Illness Index
• Somatostatin (cerebrospinal fluid)